Le Pen C - Search Results

1

Financial cost of osteoarthritis in France. The "COART" France study.

Le Pen C, Reygrobellet C, Gérentes I. Le Pen C, et al. Joint Bone Spine. 2005 Dec;72(6):567-70. doi: 10.1016/j.jbspin.2005.01.011. Epub 2005 Jun 8. Joint Bone Spine. 2005. PMID: 16226481

2

Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study.

Mazières B, Bard H, Ligier M, Bru I, d'Orsay GG, Le Pen C. Mazières B, et al. Among authors: le pen c. Joint Bone Spine. 2007 Oct;74(5):453-60. doi: 10.1016/j.jbspin.2007.01.037. Epub 2007 Aug 9. Joint Bone Spine. 2007. PMID: 17921022

3

[Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France].

Priol G, Maurel F, Le Pen C. Priol G, et al. Among authors: le pen c. Bull Cancer. 2005 Sep;92(9):809-16. Bull Cancer. 2005. PMID: 16203271 Free article. French.

4

The burden cost of French patients suffering from irritable bowel syndrome.

Le Pen C, Ruszniewski P, Gaudin AF, Amouretti M, Bommelaer G, Frexinos J, Poynard T, Maurel F, Priol G, Bertin C. Le Pen C, et al. Scand J Gastroenterol. 2004 Apr;39(4):336-43. doi: 10.1080/00365520310008458. Scand J Gastroenterol. 2004. PMID: 15125465

5

Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.

LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziégler M. LePen C, et al. Pharmacoeconomics. 1999 Jul;16(1):59-69. doi: 10.2165/00019053-199916010-00006. Pharmacoeconomics. 1999. PMID: 10539122 Clinical Trial.

6

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.

Rouland JF, Le Pen C; Ophthalmologists of the Glaucoma Study. Rouland JF, et al. Among authors: le pen c. Eur J Ophthalmol. 2003 Jul;13 Suppl 4:S5-20. doi: 10.1177/112067210301304s02. Eur J Ophthalmol. 2003. PMID: 12948049 Clinical Trial.

7

The drug budget silo mentality: the French case.

Le Pen C. Le Pen C. Value Health. 2003 Jul-Aug;6 Suppl 1:S10-9. doi: 10.1046/j.1524-4733.6.s1.2.x. Value Health. 2003. PMID: 12846922 Free article.

8

[A cost-effectiveness analysis of changes in therapeutic strategies in the treatment of HIV since 1996].

Le Pen C, Rozenbaum W, Downs A, Lilliu H, Maurel F, Foucher F. Le Pen C, et al. Therapie. 2002 Jan-Feb;57(1):27-33. Therapie. 2002. PMID: 12090143 French.

9

Diagnosis related group costs in a regulated environment. A note about their economic interpretation.

Le Pen C, Berdeaux G. Le Pen C, et al. Pharmacoeconomics. 2000 Feb;17(2):115-20. doi: 10.2165/00019053-200017020-00001. Pharmacoeconomics. 2000. PMID: 10947335

10

The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction.

LePen C, Lilliu H, Keller T, Fiessinger S. LePen C, et al. Pharmacoeconomics. 1998 Jul;14(1):49-58. doi: 10.2165/00019053-199814010-00005. Pharmacoeconomics. 1998. PMID: 10182194 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters